Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE LIBRE DE BRUXELLES currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, which suggests that the company is engaging with a variety of individual perspectives at the USPTO. The presence of 4 distinct art units indicates that these applications span several different technical classifications within the broader Biotechnology & Pharmaceuticals field.
The busiest examiner for the company is CATINA, MICHAEL ANTHONY, who is currently handling 1 busiest examiner pending action. This means that the 4 pending office actions are spread thinly, with no single examiner managing more than 1 of the current cases. This lack of examiner concentration may require the company to adapt to 4 different sets of prosecution styles simultaneously.
From a practitioner's perspective, the diversity shown by the 4 distinct art units and 4 distinct examiners suggests a decentralized prosecution environment. Each of the 4 pending office actions likely requires a tailored approach, as the data does not show any clustering of cases under CATINA, MICHAEL ANTHONY beyond the 1 busiest examiner pending action. The strategy must account for the unique requirements of each of the 4 distinct art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CATINA, MICHAEL ANTHONY | 1 | 31.7% | +30.6% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| FAN, LYNN Y | 1 | 47.3% | +49.8% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 23d |
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 84d |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 23d |
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 84d |
| 18482736 | WNT SIGNALING AGONIST MOLECULES | WANG, CHANG YU | — |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | — |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| 1675 | 1 |
| 1759 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18625495 | IMPROVEMENTS IN OR RELATING TO HEART MONITORING | CATINA, MICHAEL ANTHONY | 3791 | §103§112Other | Non-Final OA | 84d | Pending | Apr 03, 2024 |
| 18482736 | WNT SIGNALING AGONIST MOLECULES | WANG, CHANG YU | 1675 | §112 | Final Rejection | — | Pending | Oct 06, 2023 |
| 18553044 | Protein Tyrosine Phosphatases as Biomarkers for Hepatocellular Carcinoma and Uses Thereof | FAN, LYNN Y | 1759 | §103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 17921372 | Yeast strains for reducing contamination by lactic acid bacteria | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Non-Final OA | 23d | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE LIBRE DE BRUXELLES has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Michael Anthony Catina has the most, with 1 of UNIVERSITE LIBRE DE BRUXELLES's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
